Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...
New research suggests that alpha-1 antitrypsin could be an effective option for treating those with COVID-related acute respiratory distress syndrome (ARDS). In their study, published in the journal ...
Inflarx N.V. (($IFRX)) announced an update on their ongoing clinical study. Study Overview: The JUST BREATHE trial is a ...
Inflarx N.V. (($IFRX)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled ...
The use of intravenous magnesium sulphate for acute respiratory distress syndrome is associated with a lower rate of ...
Unlike current treatment methods, SWAZA-1 is noninvasive, simple to administer, and low-cost. The novel technology can be easily administered via nebulization, allowing for early intervention. This ...
ENGLEWOOD, Colo., Sept. 21, 2020 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") announces the receipt of an Investigational New Drug ("IND") from the U.S. Food and ...
(RTTNews) - InflaRx N.V. (IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics, announced on Wednesday that the European Commission or EC has granted marketing ...
InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress. The European Commission granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback